Pinnacle Foods Inc.

Pinnacle Foods Inc.

PF
Pinnacle Foods Inc.US flagNew York Stock Exchange
66.66
USD
-0.49
- -
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
30
30.4
21.97
23.06
22.4
22.89
26.76
26.61
26.61
Basic EPS, GAAP
0.27
-0.58
0.47
0.84
2.15
1.83
1.81
4.5
5.09
Free Cash Flow per Basic Share
3.16
2.51
1.8
2.45
4.76
3.21
4.17
3.52
4.31
Dividend per Share
- -
- -
- -
0.39
0.88
0.96
1.05
1.19
1.28
Book Value per Share
- -
2.48
2.25
2.59
3.64
4.47
5.15
8.37
8.68
Tangible Book Value per Share
- -
-28.85
-20.24
-19.72
-17.35
-16.46
-23.48
-19.14
-19.67
Basic Weighted Avg Shares
81
81
113
107
116
116
117
118
119
Sales/Revenue/Turnover
2,437
2,470
2,478
2,464
2,591
2,656
3,128
3,144
3,154
Operating Margin (%)
12.07
13.75
12.04
13.53
13.87
15.99
15.69
16.39
17.92
Depreciation Expense
78
88
98
78
81
90
106
133
106
Net Income, GAAP
22
-47
53
89
248
213
211
532
604
Effective Tax Rate (%)
25.14
- -
38.37
44.44
40.32
36.83
38.01
- -
75.26
Profit Margin (%)
0.9
-1.9
2.12
3.63
9.59
8
6.75
16.92
19.14
Working Capital
- -
391
372
461
332
452
579
471
291
LT Debt
- -
2,739
2,576
2,476
2,286
2,273
3,140
2,926
2,704
Total Equity
- -
845
889
1,598
1,714
1,806
1,949
2,380
2,432
Return on Invested Capital (%)
- -
- -
5.19
4.88
5.29
6.63
6.6
- -
- -
Return on Capital (%)
- -
- -
6.01
5.77
11.12
9.71
9.04
- -
37.77
Return on Common Equity (%)
- -
-46.62
23.08
33.69
71.24
45.25
37.67
66.9
75.24

Capital Structure

FRC

in mil. unless spec.
Dec'17
Mar'18
Jun'18
ST Debt
37
55
56
LT Borrowings
2,926
2,704
2,704
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
119
119
119
Market Capitalization
6,916
6,340
7,674

Working Capital

FRC

in mil. unless spec.
Dec'17
Mar'18
Jun'18
Total Current Assets
1,032
874
869
Cash, Cash Equivalents & STI
250
78
80
Accounts Receivable, Net
270
- -
254
Inventories
490
477
508
Total Current Liabilities
561
594
577
Payables & Accruals
525
492
466
ST Debt
37
55
56
Deferred Revenue
2
4
3

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
24.5%
22.13%
Free Cash Flow
- -
24.61%
-14.68%
Net Income, GAAP
- -
77.01%
152.02%
Sales/Revenue/Turnover
- -
5.07%
0.51%
Total Cash Common Dividend
- -
- -
14.56%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
754
756
759
858
3,128
2017
766
745
750
884
3,144
2018
779
742
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
0.21
0.39
0.45
0.75
1.81
2017
0.19
0.16
0.39
3.75
4.5
2018
0.48
0.47
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
0.26
0.26
0.25
0.29
1.05
2017
0.29
0.29
0.29
0.33
1.19
2018
0.33
0.33
- -
- -
- -

Company Description

APIChat
Sector
Consumer Defensive
Industry
Packaged Foods
Address
IPO Date
Mar 28, 2013
Business
Pinnacle Foods Inc. was formerly a prominent packaged food company that focused on both shelf-stable and frozen food products in North America. The company's brand portfolio included well-known names such as Birds Eye, Duncan Hines, Earth Balance, Gardein, Hungry-Man, Vlasic, and Wish-Bone, spanning various categories from frozen vegetables and meals to baking mixes and condiments. In a significant industry event, Pinnacle Foods was acquired by Conagra Brands, Inc. in a transaction valued at approximately $10.9 billion. The acquisition was publicly announced on June 27, 2018, and officially completed on October 26, 2018, leading to Pinnacle Foods becoming a subsidiary of Conagra. Consequently, the company's stock, previously traded under the ticker PF, was delisted from the New York Stock Exchange. Its established brands are now integrated into Conagra Brands' extensive product offerings.

Company News

APIChat
  • Reviewing Pinnacle Food Group (NASDAQ:PFAI) and Mission Produce (NASDAQ:AVO)

  • Head to Head Survey: Pinnacle Food Group (NASDAQ:PFAI) and Corteva (NYSE:CTVA)

  • MedLumics® Announces the Publication of FIM Results for the AblaView® (PF) Ablation System in (AF) Patients, Including Clinical Safety and Our Ability to Predict Durable Lesions at 3 Months With 100% Specificity

  • Pharma Giants Go After $10 Billion Market With RSV Drugs